homehealthcare NewsDavos 2023 | Dr Reddy's will continue to allocate capital for inorganic growth in India
Davos 2023 | Dr Reddy's will continue to allocate capital for inorganic growth in India
Speaking to CNBC-TV18’s Shereen Bhan, GV Prasad, Co-Chairman and MD of Dr Reddy's, said that India is a priority for his company. He said DRL would continue to allocate capital for inorganic growth in India.
The outlook for the pharmaceutical sector in 2023 appears to be positive, with companies like Dr Reddy's seeing potential for growth in the US market and a favourable environment for investment in India. During the World Economic Forum meeting in Davos, GV Prasad, co-chairman and MD of Dr Reddy's, told CNBC-TV18 that India was a priority for his company and the firm would continue to allocate capital for inorganic growth in the country.
“India is a big priority for Dr Reddy's. If you see the last three, four or five years, that is where we have put on maximum capital in terms of inorganic (investment). Of course, we are open to value add in transactions wherever there will be, but our bias is towards branded markets and in that, India would be foremost,” Prasad said.
Read Here | Davos 2023 | India incredibly important, predicted to grow at 6%, says Bank of America CEO
Prasad emphasised that the US market was still attractive and would remain an important part of every large generic company in India.
He said, “The US continues to be the largest generic market in the world. It is a market which is quite transparent and easy to get in. Companies have to innovate have to find ways to get growth, market share and all of that. And I think the biggest competition is from our Indian companies.”
Prasad states that many governments worldwide are pushing for the localisation of the pharma value chain, which benefits Indian companies like Dr Reddy's.
He said, “The PLI is certainly encouraging for companies to invest in our active ingredients and go backwards and move the supply chain back to India. We are seeing this kind of trend globally, many governments are encouraging the localisation of the pharmaceutical value chain. So, in a sense, what India has done is good for the industry and the country. How much impact it will have, I think we have to see. It will take a couple of years to gain momentum. But in the long term, it certainly will help.”
Prasad acknowledged that the generic business operates under pricing pressure but said they have bottomed out on the worst in the US market. He added that pricing pressure in the US will always be there.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Rapido offers free rides to voters to polling stations on May 13 in Hyderabad, 3 other cities
May 6, 2024 5:49 PM
Lok Sabha elections 2024: Seats to date, all you need to know about third phase of voting
May 6, 2024 4:49 PM
Concerns on low voter turnout a "myth"; absolute number of voters correct way to analyse: Report
May 6, 2024 2:57 PM
Haryana Lok Sabha elections 2024: A look at JJP candidates
May 6, 2024 2:26 PM